Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of BMS-986020 on Probe Substrates PK
NCT02227173Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2014
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bms-986020 in idiopathic pulmonary fibrosis (IPF), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum Observed Plasma Concentration and Area Under the Concentration-Time Curve. Started Sep 2014; status: completed.
02
Drugs
bms-986020
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT02227173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02227173.